Table 2.
Multivariable Cox regression analysis in the training cohort
| Variables | Disease‐free survival | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| CEA (ng/mL) (elevated vs normal) | 1.617 (1.110‐2.354) | 0.012 | 1.504 (1.013‐2.234) | 0.043 |
| Depth of invasion | 0.0002 | 0.006 | ||
| T4b | Reference | Reference | ||
| T1 | 0.001 (0.0001‐999) | 0.959 | 0.001 (0.0001‐999) | 0.955 |
| T2 | 0.299 (0.128‐0.701) | 0.005 | 0.394 (0.158‐0.980) | 0.045 |
| T3 | 0.445 (0.272‐0.727) | 0.001 | 0.557 (0.335‐0.926) | 0.024 |
| T4a | 1.067 (0.537‐2.121) | 0.854 | 1.233 (0.630‐2.414) | 0.541 |
| Lymph node metastasis | 0.001 | <0.0001 | ||
| N0 | Reference | Reference | ||
| N1 | 2.225 (1.467‐3.375) | 0.0002 | 2.290 (1.463‐3.582) | 0.0003 |
| N2 | 1.927 (1.134‐3.273) | 0.015 | 3.088 (1.811‐5.264) | <0.0001 |
| Metastasis (M1 vs M0) | 1.838 (1.141‐2.963) | 0.012 | 2.479 (1.521‐4.040) | 0.0003 |
| IL‐37 (high vs low) | 0.588 (0.402‐0.859) | 0.006 | 0.559 (0.374‐0.836) | 0.005 |
| CD66b (high vs low) | 1.749 (1.193‐2.564) | 0.004 | 2.028 (1.364‐3.014) | 0.0005 |
| MMR status (pMMR vs dMMR) | 3.281 (1.645‐6.545) | 0.001 | 3.770 (1.729‐8.218) | 0.001 |
CEA, carcino‐embryonic antigen.